AG2R LA Mondiale Gestion D Actifs Acquires New Shares in Stryker Corporation $SYK

Key Points

• AG2R LA Mondiale Gestion D Actifs has acquired 12,795 shares of Stryker Corporation valued at approximately $4.9 million during the first quarter.
• Stryker recently reported a quarterly earnings of $3.13 per share, surpassing analysts' expectations by $0.06, with revenues of $6.02 billion for the quarter.
• The company has announced a quarterly dividend of $0.84, reflecting an annualized yield of 0.9%, with a dividend payout ratio of 44.50%.

AG2R LA Mondiale Gestion D Actifs acquired a new stake in Stryker Corporation (NYSE:SYK - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 12,795 shares of the medical technology company's stock, valued at approximately $4,896,000.

Several other hedge funds have also recently bought and sold shares of SYK. Brighton Jones LLC boosted its stake in shares of Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock valued at $1,643,000 after acquiring an additional 609 shares during the last quarter. Gotham Asset Management LLC increased its position in Stryker by 139.8% during the 4th quarter. Gotham Asset Management LLC now owns 4,251 shares of the medical technology company's stock worth $1,531,000 after purchasing an additional 2,478 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Stryker by 1.3% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 60,503 shares of the medical technology company's stock worth $21,784,000 after purchasing an additional 754 shares in the last quarter. Nomura Holdings Inc. increased its position in Stryker by 220.2% during the 4th quarter. Nomura Holdings Inc. now owns 15,925 shares of the medical technology company's stock worth $5,734,000 after purchasing an additional 10,951 shares in the last quarter. Finally, Pathstone Holdings LLC increased its position in Stryker by 0.7% during the 4th quarter. Pathstone Holdings LLC now owns 52,763 shares of the medical technology company's stock worth $19,008,000 after purchasing an additional 371 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Price Performance

Shares of Stryker stock opened at $388.68 on Friday. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The stock has a market capitalization of $148.60 billion, a P/E ratio of 51.48, a PEG ratio of 2.76 and a beta of 0.93. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The business's fifty day moving average price is $389.15 and its 200 day moving average price is $379.70.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm had revenue of $6.02 billion for the quarter, compared to analysts' expectations of $5.92 billion. During the same quarter last year, the firm earned $2.81 earnings per share. The firm's revenue for the quarter was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. Stryker's dividend payout ratio (DPR) is presently 44.50%.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the transaction, the director directly owned 3,222,108 shares of the company's stock, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Viju Menon sold 500 shares of the firm's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on SYK. Needham & Company LLC lifted their price objective on Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Wells Fargo & Company raised their price objective on Stryker from $435.00 to $445.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Citigroup restated a "buy" rating and set a $455.00 price objective (up previously from $443.00) on shares of Stryker in a report on Thursday, May 22nd. BTIG Research restated a "buy" rating on shares of Stryker in a report on Monday, July 14th. Finally, Wall Street Zen upgraded Stryker from a "hold" rating to a "buy" rating in a report on Friday, July 18th. Fourteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $431.42.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.